The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Aust, Stefanie ^a   Horak, Peter ^a   Pils, Dietmar ^a   Pils, Sophie ^a   Grimm, Christoph ^a   Horvat, Reinhard ^a   Tong, Dan ^a   Schmid, Bernd ^b   Speiser, Paul ^a   Reinthaller, Alexander ^a   Polterauer, Stephan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital Vienna   (Austria)

Author keywords

Estrogen receptor alpha; Estrogen receptor beta; Immunohistochemistry; Ovarian cancer; PELP1; Prognosis

Indexed keywords

CARBOPLATIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ONCOPROTEIN; PACLITAXEL; PROLINE GLUTAMIC ACID LEUCINE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DISEASE MARKER; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA; CO-REPRESSOR PROTEINS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874932994     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-115     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Gallo D, Ferlini C, Scambia G. The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer. Curr Drug Targets 2010, 11(4):474-481. 10.2174/138945010790980385, 20015012.
3. Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008, 22(9):2085-2098. 10.1210/me.2007-0512, 18550773.
4. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996, 10(10):1167-1177. 10.1210/me.10.10.1167, 9121485.
5. O'Malley BW. Coregulators: from whence came these "master genes". Mol Endocrinol 2007, 21(5):1009-1013. 10.1210/me.2007-0012, 17284664.
6. Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK. Regulation of rDNA transcription by proto-oncogene PELP1. PLoS One 2011, 6(6):e21095. 10.1371/journal.pone.0021095, 3113909, 21695158.
7. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007, 5:e004. 1876599, 17525794.
8. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A 2002, 99(23):14783-14788. 10.1073/pnas.192569699, 137496, 12415108.
9. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 2004, 89(12):6130-6138. 10.1210/jc.2004-0909, 1262662, 15579769.
10. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, Brann D, Sun LZ, Yeh IT. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res 2010, 70(10):4092-4101. 10.1158/0008-5472.CAN-09-3834, 2889925, 20460518.
11. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 2010, 120(3):603-612. 10.1007/s10549-009-0419-9, 19495959.
12. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 2011, 17(8):2250-2259. 10.1158/1078-0432.CCR-10-2718, 21421858.
13. Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res 2008, 68(12):4902-4909. 10.1158/0008-5472.CAN-07-5698, 18559538.
14. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007, 18(5):1051-1059.
15. Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N, Friese K, Mylonas I. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2010, 281(3):511-517. 10.1007/s00404-009-1185-y, 19639330.
16. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009, 114(3):480-485. 10.1016/j.ygyno.2009.05.045, 2756056, 19560192.
17. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005, 96(3):671-677. 10.1016/j.ygyno.2004.11.010, 15721410.
18. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000, 89(8):1783-1791. 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D, 11042574.
19. Remmele W. Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8(3):138-140.
20. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005, 24(1):4-25.
21. Cho KR. Shih Ie M: Ovarian cancer. Annu Rev Pathol 2009, 4:287-313. 10.1146/annurev.pathol.4.110807.092246, 2679364, 18842102.
22. Lindgren PR, Cajander S, Backstrom T, Gustafsson JA, Makela S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004, 221(1-2):97-104.
23. Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011, 17(3):511-518. 10.1007/s12253-010-9340-0, 3158974, 21207255.
24. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 2009, 19(4):620-627. 10.1111/IGC.0b013e3181a44b62, 19509560.
25. Chakravarty D, Tekmal RR, Vadlamudi RK. PELP1: A novel therapeutic target for hormonal cancers. IUBMB Life 2010, 62(3):162-169. 2997573, 20014005.
26. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 2012, 14(4):R108. 10.1186/bcr3229, 22812534.
27. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 2007, 67(11):5505-5512. 10.1158/0008-5472.CAN-06-3647, 2774841, 17545633.
28. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H. Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. Cell Oncol 2009, 31(3):235-247.